{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:17:25Z","timestamp":1787498245691,"version":"build-2736575974"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>\n                    Balancing thromboembolic prevention against bleeding complications remains a critical challenge in anticoagulant therapy. While established bleeding risk assessment models (RAMs) such as HAS-BLED and HEMORR\n                    <jats:sub>2<\/jats:sub>\n                    HAGES were initially developed for warfarin-treated patients, their applicability to non-vitamin K antagonist oral anticoagulant (NOAC) users and venous thromboembolism (VTE) populations remained uncertain. This review synthesized recent advancements in bleeding risk stratification for atrial fibrillation (AF) and VTE patients, focusing on model performance, drug-specific adaptations, and emerging biomarker-driven approaches. For AF patients, traditional RAMs (HAS-BLED, HEMORR\n                    <jats:sub>2<\/jats:sub>\n                    HAGES, ATRIA) demonstrated moderate predictive accuracy (AUC: 0.55\u20130.74) in NOAC cohorts, with HEMORR\n                    <jats:sub>2<\/jats:sub>\n                    HAGES showing superior discrimination in certain studies. The biomarker-integrated ABC (incorporating GDF-15, troponin, hemoglobin) and the NOAC-specific DOAC score, have shown improved risk stratification, with the latter demonstrating a higher C-statistic than HAS-BLED. In VTE populations, the IMPROVE (AUC: 0.62\u20130.73) effectively identified high-risk medical inpatients, while the RIETE (major bleeding incidence: 0.1%\u20136.2%) and EINSTEIN (C-statistic: 0.68\u20130.74) addressed dynamic risks during anticoagulation. However, heterogeneity in validation cohorts, endpoint definitions (e.g., ISTH vs. TIMI criteria), and static risk factor selections limited cross-model generalizability. Current RAMs exhibited variable performance across anticoagulant regimens and clinical contexts highlighting the need for next-generation models that integrate dynamic risk modifiers (e.g., transient anemia, antiplatelet use) and biomarker-based approaches. While NOAC-specific tools such as the DOAC may be more appropriate for AF patients, context-adapted models like IMPROVE and RIETE are better suited for VTE populations. Future research should prioritize real-world validation, machine learning integration, and the standardization of bleeding definitions to advance precision anticoagulation strategies.\n                  <\/jats:p>","DOI":"10.3389\/fcvm.2025.1645823","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:32:52Z","timestamp":1762842772000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Research progress on bleeding risk assessment models in anticoagulant therapy"],"prefix":"10.3389","volume":"12","author":[{"given":"Li","family":"Sen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Kangpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Yihui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"euaf027","DOI":"10.1093\/europace\/euaf027","article-title":"Global, regional, and national burden of atrial fibrillation and atrial flutter from 1990 to 2021: sex differences and global burden projections to 2046-a systematic analysis of the global burden of disease study 2021","volume":"27","author":"Tan","year":"2025","journal-title":"Europace"},{"key":"B2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/jce.15759","article-title":"Atrial fibrillation: epidemiology, pathophysiology, and clinical complications (literature review)","volume":"34","author":"Bizhanov","year":"2023","journal-title":"J Cardiovasc Electrophysiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1111\/jth.15776","article-title":"Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: communication from the isth ssc subcommittee on predictive and diagnostic variables in thrombotic disease","volume":"20","author":"den Exter","year":"2022","journal-title":"J Thromb Haemost"},{"key":"B4","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/jth.12501","article-title":"Major bleeding during secondary prevention of venous thromboembolism in patients who have completed anticoagulation: a systematic review and meta-analysis","volume":"12","author":"Castellucci","year":"2014","journal-title":"J Thromb Haemost"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.7326\/M21-1094","article-title":"Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: a systematic review and meta-analysis","volume":"174","author":"Khan","year":"2021","journal-title":"Ann Intern Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/jth.14738","article-title":"Considerations when choosing an appropriate bleeding risk assessment tool for patients with atrial fibrillation","volume":"18","author":"Ding","year":"2020","journal-title":"J Thromb Haemostasis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.jacc.2012.06.019","article-title":"Performance of the hemorr(2)Hages, atria, and has-bled bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the amadeus (evaluating the use of Sr34006 compared to warfarin or acenocoumarol in patients with atrial","volume":"60","author":"Apostolakis","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/j.amjcard.2017.07.051","article-title":"Comparison of the cha(2)Ds(2)-vasc, chads(2), has-bled, orbit, and atria risk scores in predicting non-vitamin K antagonist oral anticoagulants-associated bleeding in patients with atrial fibrillation","volume":"120","author":"Yao","year":"2017","journal-title":"Am J Cardiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00228-020-03015-7","article-title":"Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants-a Swedish, register-based cohort study in atrial fibrillation outpatients","volume":"77","author":"Holm","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10557-023-07521-5","article-title":"Pharmacodynamic drug-drug interactions and bleeding outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study","volume":"39","author":"Grymonprez","year":"2025","journal-title":"Cardiovasc Drugs Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10557-021-07232-9","article-title":"Severe bleeding risk of direct oral anticoagulants versus vitamin K antagonists for stroke prevention and treatment in patients with atrial fibrillation: a systematic review and network meta-analysis","volume":"37","author":"Xu","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/bcp.15491","article-title":"A new model to predict the risk of major gastrointestinal bleeding in patients on direct oral anticoagulants (dabigatran and rivaroxaban)","volume":"89","author":"Lv","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.jacc.2017.06.030","article-title":"Biomarker-based risk model to predict cardiovascular mortality in patients with stable coronary disease","volume":"70","author":"Lindholm","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.amjcard.2013.05.013","article-title":"Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure","volume":"112","author":"Lok","year":"2013","journal-title":"Am J Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.jcin.2018.12.031","article-title":"Critical appraisal of contemporary clinical endpoint definitions in coronary intervention trials: a guidance document","volume":"12","author":"Spitzer","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"B16","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1161\/CIRCULATIONAHA.123.064556","article-title":"Development and validation of the doac score: a novel bleeding risk prediction tool for patients with atrial fibrillation on direct-acting oral anticoagulants","volume":"148","author":"Aggarwal","year":"2023","journal-title":"Circulation"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1177\/1060028020933186","article-title":"Validation of bleeding risk prediction scores for patients with major bleeding on direct oral anticoagulants","volume":"54","author":"Tchen","year":"2020","journal-title":"Ann Pharmacother"},{"key":"B18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the esc","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"B20","doi-asserted-by":"publisher","first-page":"102285","DOI":"10.1016\/j.rpth.2023.102285","article-title":"Risk scores for major bleeding from direct oral anticoagulants: comparing predictive performance in patients with atrial fibrillation","volume":"8","author":"Campos-Staffico","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"B21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/fampra\/cmad121","article-title":"Oral anticoagulant safety in family practice: prognostic accuracy of bleeding risk scores (from the Cacao study)","volume":"41","author":"Gaboreau","year":"2024","journal-title":"Fam Pract"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1019986","DOI":"10.3389\/fcvm.2022.1019986","article-title":"Performance of the abc-bleeding risk score for assessing major bleeding risk in Chinese patients with atrial fibrillation on oral anticoagulation therapy: a real-world study","volume":"9","author":"Wang","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1378\/chest.09-3081","article-title":"Factors at admission associated with bleeding risk in medical patients: findings from the improve investigators","volume":"139","author":"Decousus","year":"2011","journal-title":"Chest"},{"key":"B24","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1160\/TH16-01-0003","article-title":"External validation of the improve bleeding risk assessment model in medical patients","volume":"116","author":"Rosenberg","year":"2016","journal-title":"Thromb Haemost"},{"key":"B25","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/crj.13467","article-title":"Risk assessment of venous thromboembolism and bleeding in COVID-19 patients","volume":"16","author":"Wang","year":"2022","journal-title":"Clin Respir J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.thromres.2023.08.003","article-title":"Prediction of in-hospital bleeding in acutely ill medical patients: external validation of the improve bleeding risk score","volume":"230","author":"Villiger","year":"2023","journal-title":"Thromb Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"100054","DOI":"10.1016\/j.lanwpc.2020.100054","article-title":"Validation of the improve bleeding risk score in Chinese medical patients during hospitalization: findings from the dissolve-2 study","volume":"4","author":"Zhang","year":"2020","journal-title":"Lancet Reg Health West Pac"},{"key":"B28","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1160\/TH14-01-0081","article-title":"Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism. A multicentre retrospective cohort study","volume":"112","author":"Riva","year":"2014","journal-title":"Thromb Haemost"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e007901","DOI":"10.1161\/JAHA.117.007901","article-title":"Risk stratification for bleeding complications in patients with venous thromboembolism: application of the has-bled bleeding score during the first 6 months of anticoagulant treatment","volume":"7","author":"Brown","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"B30","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1055\/a-1339-9987","article-title":"Bleeding risk assessment in patients with venous thromboembolism","volume":"41","author":"Nopp","year":"2021","journal-title":"Hamostaseologie"},{"key":"B31","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1001\/archinte.159.5.457","article-title":"Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism","volume":"159","author":"Kuijer","year":"1999","journal-title":"Arch Intern Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijcard.2020.11.075","article-title":"Predictive value of the Kuijer score for bleeding and other adverse in-hospital events in patients with venous thromboembolism","volume":"329","author":"Keller","year":"2021","journal-title":"Int J Cardiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for Vte disease: chest guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"B34","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/jth.14396","article-title":"The American college of chest physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism: reply","volume":"17","author":"Palareti","year":"2019","journal-title":"J Thromb Haemost"},{"key":"B35","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1160\/TH08-03-0193","article-title":"Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the Riete registry","volume":"100","author":"Ruiz-Gimenez","year":"2008","journal-title":"Thromb Haemost"},{"key":"B36","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/crj.12993","article-title":"Comparison of prediction value of four bleeding risk scores for pulmonary embolism with anticoagulation: a real-world study in Chinese patients","volume":"13","author":"Zhang","year":"2019","journal-title":"Clin Respir J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejim.2019.08.002","article-title":"D-dimer levels enhance the discriminatory capacity of bleeding risk scores for predicting in-hospital bleeding events in acute pulmonary embolism","volume":"69","author":"Skowronska","year":"2019","journal-title":"Eur J Intern Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1136\/ebm.11.4.120","article-title":"The outpatient bleeding risk Index predicted major bleeding in patients taking warfarin","volume":"11","author":"Eikelboom","year":"2006","journal-title":"Evid Based Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1001\/archinte.163.8.917","article-title":"The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism","volume":"163","author":"Wells","year":"2003","journal-title":"Arch Intern Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1160\/TH15-06-0474","article-title":"Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists","volume":"115","author":"Nisio","year":"2016","journal-title":"Thromb Haemost"},{"key":"B41","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1055\/s-0041-1735251","article-title":"Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score","volume":"122","author":"de Winter","year":"2022","journal-title":"Thromb Haemost"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1160\/TH17-03-0162","article-title":"Derivation and validation of a novel bleeding risk score for elderly patients with venous thromboembolism on extended anticoagulation","volume":"117","author":"Seiler","year":"2017","journal-title":"Thromb Haemost"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1055\/s-0041-1726345","article-title":"Comparison of bleeding risk scores in elderly patients receiving extended anticoagulation with vitamin K antagonists for venous thromboembolism","volume":"121","author":"Frei","year":"2021","journal-title":"Thromb Haemost"},{"key":"B44","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/jth.14691","article-title":"Validation of the vte-bleed score\u2019s long-term performance for major bleeding in patients with venous thromboembolisms: from the command vte registry","volume":"18","author":"Nishimoto","year":"2020","journal-title":"J Thromb Haemost"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1055\/s-0040-1712913","article-title":"Venous thromboembolic diseases: diagnosis, management and thrombophilia testing: observations on nice guideline [Ng158]","volume":"120","author":"Schulman","year":"2020","journal-title":"Thromb Haemost"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/archinte.164.15.1653","article-title":"Outcomes and cost of deep venous thrombosis among patients with cancer","volume":"164","author":"Elting","year":"2004","journal-title":"Arch Intern Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1200\/jco.2000.18.17.3078","article-title":"Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis","volume":"18","author":"Hutten","year":"2000","journal-title":"J Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e026388","DOI":"10.1161\/jaha.121.026388","article-title":"Performance of the has-bled, orbit, and atria bleeding risk scores on a cohort of 399,344 hospitalized patients with atrial fibrillation and cancer: data from the French national hospital discharge database","volume":"11","author":"Pastori","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"B50","doi-asserted-by":"publisher","first-page":"oeae053","DOI":"10.1093\/ehjopen\/oeae053","article-title":"Performance of cha(2)Ds(2)-vasc and has-bled in predicting stroke and bleeding in atrial fibrillation and cancer","volume":"4","author":"Ajabnoor","year":"2024","journal-title":"Eur Heart J Open"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1645823\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:32:53Z","timestamp":1762842773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1645823\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":50,"alternative-id":["10.3389\/fcvm.2025.1645823"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1645823","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"article-number":"1645823"}}